

**Amendments to the Specification:**

Please replace the paragraph beginning on page 15, line 1, with the following rewritten paragraph:

-- Many art-recognized methods are available for introducing polynucleotides, such as the constructs of the invention, into cells. The conventional methods that can be employed, include, *e.g.*, transfection (*e.g.*, mediated by DEAE-Dextran or calcium phosphate precipitation), infection via a viral vector (*e.g.*, retrovirus, adenovirus, adeno-associated virus, lentivirus, pseudotyped retrovirus or poxvirus vectors), injection, such as microinjection, electroporation, sonoporation, a gene gun, liposome delivery (*e.g.*, LIPOFECTIN<sup>®</sup> Lipofectin<sup>®</sup> (a cation liposome containing N-[1-(2, 3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA)), LIPOFECTAMINE<sup>®</sup> (a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA)) Lipofectamine<sup>®</sup> (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT<sup>®</sup> Superfect<sup>®</sup> (polyamidoamino dendrimers) (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM<sup>®</sup> Transfectam<sup>®</sup> (dioctadecylamidoglycylspermine) (Promega Biotec, Inc., Madison, WI), or other liposomes developed according to procedures standard in the art), or receptor-mediated uptake and other endocytosis mechanisms.